EP0362278A4 - Autocrine motility factors in cancer diagnosis and management. - Google Patents

Autocrine motility factors in cancer diagnosis and management.

Info

Publication number
EP0362278A4
EP0362278A4 EP19880905318 EP88905318A EP0362278A4 EP 0362278 A4 EP0362278 A4 EP 0362278A4 EP 19880905318 EP19880905318 EP 19880905318 EP 88905318 A EP88905318 A EP 88905318A EP 0362278 A4 EP0362278 A4 EP 0362278A4
Authority
EP
European Patent Office
Prior art keywords
management
cancer diagnosis
autocrine motility
motility factors
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19880905318
Other languages
German (de)
French (fr)
Other versions
EP0362278A1 (en
Inventor
Lance A Liotta
Elliott Schiffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services (HHS)
US Departament of Commerce
Original Assignee
US Department of Health and Human Services (HHS)
US Departament of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5838187A priority Critical
Application filed by US Department of Health and Human Services (HHS), US Departament of Commerce filed Critical US Department of Health and Human Services (HHS)
Publication of EP0362278A1 publication Critical patent/EP0362278A1/en
Publication of EP0362278A4 publication Critical patent/EP0362278A4/en
Priority to US58381 priority
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038Kidney, bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4706Regulators; Modulating activity stimulating, promoting or activating activity
EP19880905318 1987-06-05 1988-05-27 Autocrine motility factors in cancer diagnosis and management. Withdrawn EP0362278A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US5838187A true 1987-06-05 1987-06-05
US58381 2005-02-15

Publications (2)

Publication Number Publication Date
EP0362278A1 EP0362278A1 (en) 1990-04-11
EP0362278A4 true EP0362278A4 (en) 1990-05-14

Family

ID=22016462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880905318 Withdrawn EP0362278A4 (en) 1987-06-05 1988-05-27 Autocrine motility factors in cancer diagnosis and management.

Country Status (6)

Country Link
EP (1) EP0362278A4 (en)
JP (1) JP2851288B2 (en)
AU (1) AU614755B2 (en)
CA (1) CA1310902C (en)
IL (1) IL86577A (en)
WO (1) WO1988009797A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (en) * 1986-10-20 1988-08-22 Trion Forskning & Utveckling New pertussis toxin polypeptides and antigens and test kits, vaccines and intradermal hudtestkompositioner
US5449753A (en) * 1992-01-17 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis
US5382521A (en) * 1992-07-14 1995-01-17 Michigan Cancer Foundation Method of determining metastatic potential of bladder tumor cells
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
DE19847107A1 (en) * 1998-10-13 2000-04-20 Herbert Ruebben Use of pertussis toxin to prepare a pharmaceutical composition for treating tumors, especially carcinomas or sarcomas
CN101926993B (en) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 Adjuvant systems and vaccines
WO2001074897A2 (en) * 2000-04-03 2001-10-11 Curagen Corporation Protein amf-1 to amf-10 and nucleic acids encoding the same
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
KR20070116652A (en) 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
PL2384765T3 (en) 2005-12-22 2017-05-31 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae vaccine
MX2009003325A (en) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vaccine comprising an oil in water emulsion adjuvant.
EP2433648A3 (en) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
BRPI0710210A2 (en) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A immunogenic composition, vaccine, methods for preparing the vaccine, and for preventing or treating staphylococcal infection, use of the immunogenic composition, and process for conjugating oligosaccharide or capsular polysaccharide
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP2422810B1 (en) 2006-07-17 2014-10-22 GlaxoSmithKline Biologicals s.a. Influenza vaccine
EA200900032A1 (en) 2006-07-18 2011-02-28 Глаксосмитклайн Байолоджикалс С.А. Vaccines against malaria
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
PE20090146A1 (en) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa immunogenic composition against influenza virus
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
PL2271360T3 (en) 2008-04-16 2016-03-31 Glaxosmithkline Biologicals Sa Vaccine
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
EP2552480A1 (en) 2010-03-26 2013-02-06 GlaxoSmithKline Biologicals S.A. Hiv vaccine
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CN104244974A (en) 2011-05-13 2014-12-24 硕腾有限公司 Hendra and nipah virus g glycoprotein immunogenic compositions
CN103533953A (en) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 Vaccine against streptococcus pneumoniae
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
ES2721930T3 (en) 2012-12-05 2019-08-06 Glaxosmithkline Biologicals Sa Immunogenic composition
AU2014366281A1 (en) 2013-12-16 2016-05-26 Zoetis Services Llc Hendra and Nipah virus G glycoprotein immunogenic compositions
SI3160500T1 (en) 2014-06-25 2019-11-29 Glaxosmithkline Biologicals Sa Clostridium difficile immunogenic composition
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
CN110621339A (en) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
FR3066920A1 (en) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals Sa
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 102, 1985, page 195, abstract no. 216406j, Columbus, Ohio, US; F.C. PATTERSON et al.: "The effect of ionophores and related agents on the induction of doming in a rat mammary epithelial cell line", & J. CELL. PHYSIOL. 1985, 123(1), 89-100 *
NATURE, vol. 272, 1978, pages 725-727, Macmillan Journals Ltd; J.A. MELERO et al.: "Possible transcriptional control of three polypeptides which accumulate in a temperature-sensitive mamalian cell line"Complete article *
See also references of WO8809797A1 *

Also Published As

Publication number Publication date
WO1988009797A1 (en) 1988-12-15
JPH04502143A (en) 1992-04-16
EP0362278A1 (en) 1990-04-11
AU1803488A (en) 1989-01-04
IL86577D0 (en) 1988-11-15
AU614755B2 (en) 1991-09-12
JP2851288B2 (en) 1999-01-27
CA1310902C (en) 1992-12-01
IL86577A (en) 1993-06-10

Similar Documents

Publication Publication Date Title
DE58903221D1 (en) Sulfamoylphenylharnstoffe.
DE68913194D1 (en) Therapeutische chinuclidinderivate.
DE68918595D1 (en) Matrix-septum.
DE68906834D1 (en) Pyrimidopyrimidinderivate.
DE3761285D1 (en) Sperrmechanismus fuer prothesenteile.
DE68925029D1 (en) Shuntregelvorrichtung.
GB2228712B (en) Data cards.
DE58901919D1 (en) Transdermale monolithsysteme.
DE3789017D1 (en) Eucaryotisches expressionssystem.
DE3772912D1 (en) Osteosyntheses implantatset.
DE3777539D1 (en) Suessungsmittelzusammensetzung.
DE3786250D1 (en) Phosphinsaeure-derivate.
DE3776060D1 (en) Polyphenylenaetherzusammensetzung.
DE3879852D1 (en) Differentialkorrelationsanalysator.
DE3878589D1 (en) Buerstendichtungen.
DE3772064D1 (en) Porphyrinderivate.
DE3876824D1 (en) Waeschehandhabungswagen.
DE3780650D1 (en) Wuerfelpresse.
DE3864664D1 (en) Koerperstativ.
DE3881066D1 (en) Duennschichttransistor.
DE3866200D1 (en) Oelablassventil.
DE68911805D1 (en) Phasenrauschmesseinrichtung.
DE3776328D1 (en) Halographisches abtastsystem.
DE3854331D1 (en) Eisnachweisschaltung.
DE3878959D1 (en) Aba-block-copolymere.

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19891030

A4 Despatch of supplementary search report

Effective date: 19900514

17Q First examination report

Effective date: 19920508

18D Deemed to be withdrawn

Effective date: 19920919